SANOFI-ADR (SNY) Stock Fundamental Analysis
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 198 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth Finally SNY also has an excellent dividend rating. With these ratings, SNY could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.00%, SNY belongs to the top of the industry, outperforming 92.42% of the companies in the same industry.
With an excellent Return On Equity value of 15.37%, SNY belongs to the best of the industry, outperforming 89.90% of the companies in the same industry.
With an excellent Return On Invested Capital value of 15.58%, SNY belongs to the best of the industry, outperforming 91.92% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 41.67%.
The last Return On Invested Capital (15.58%) for SNY is above the 3 year average (7.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9% | ||
| ROE | 15.37% | ||
| ROIC | 15.58% |
ROA(3y)5.07%
ROA(5y)6.23%
ROE(3y)8.63%
ROE(5y)10.88%
ROIC(3y)7.46%
ROIC(5y)7.05%
1.3 Margins
With an excellent Profit Margin value of 12.97%, SNY belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
SNY's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 22.04%, SNY belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 70.04%, SNY is in the better half of the industry, outperforming 76.26% of the companies in the same industry.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.04% | ||
| PM (TTM) | 12.97% | ||
| GM | 70.04% |
OM growth 3Y0.02%
OM growth 5Y3.47%
PM growth 3Y-6.53%
PM growth 5Y12.13%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
SNY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, SNY has less shares outstanding
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of SNY is 3.04, which is a good value as it means it would take SNY, 3.04 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.04, SNY belongs to the best of the industry, outperforming 90.40% of the companies in the same industry.
SNY has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
SNY has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: SNY outperforms 47.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.04 | ||
| Altman-Z | N/A |
ROIC/WACC2.12
WACC7.35%
2.3 Liquidity
A Current Ratio of 1.46 indicates that SNY should not have too much problems paying its short term obligations.
With a Current ratio value of 1.46, SNY is not doing good in the industry: 71.21% of the companies in the same industry are doing better.
A Quick Ratio of 0.74 indicates that SNY may have some problems paying its short term obligations.
With a Quick ratio value of 0.74, SNY is not doing good in the industry: 83.84% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased strongly by -12.99% in the last year.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
The Revenue has grown by 30.30% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-12.99%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-53.61%
Revenue 1Y (TTM)30.3%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-12.62%
3.2 Future
Based on estimates for the next years, SNY will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.23% on average per year.
SNY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.33% yearly.
EPS Next Y8.37%
EPS Next 2Y9.02%
EPS Next 3Y8.18%
EPS Next 5Y8.23%
Revenue Next Year3.46%
Revenue Next 2Y5.06%
Revenue Next 3Y5.29%
Revenue Next 5Y4.33%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNY is valuated correctly with a Price/Earnings ratio of 14.36.
Compared to the rest of the industry, the Price/Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 86.36% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.22, SNY is valued a bit cheaper.
A Price/Forward Earnings ratio of 10.60 indicates a reasonable valuation of SNY.
SNY's Price/Forward Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 88.38% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.86. SNY is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.36 | ||
| Fwd PE | 10.6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaper than 94.95% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 83.33% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.27 | ||
| EV/EBITDA | 5.31 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)1.72
PEG (5Y)2.82
EPS Next 2Y9.02%
EPS Next 3Y8.18%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.09%, which is a nice return.
SNY's Dividend Yield is rather good when compared to the industry average which is at 4.25. SNY pays more dividend than 95.45% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.09% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.34%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
SNY has decreased its dividend recently.
Dividend Growth(5Y)4.34%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
39.72% of the earnings are spent on dividend by SNY. This is a low number and sustainable payout ratio.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.72%
EPS Next 2Y9.02%
EPS Next 3Y8.18%
55.44
+1.34 (+2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners39.32%
Inst Owner Change0.2%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap135.72B
Analysts80
Price Target68.52 (23.59%)
Short Float %0.18%
Short Ratio1.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.09% |
Yearly Dividend2.18
Dividend Growth(5Y)4.34%
DP39.72%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.16%
Min EPS beat(2)-2.18%
Max EPS beat(2)14.5%
EPS beat(4)3
Avg EPS beat(4)4.59%
Min EPS beat(4)-2.18%
Max EPS beat(4)14.5%
EPS beat(8)5
Avg EPS beat(8)2.9%
EPS beat(12)8
Avg EPS beat(12)3.44%
EPS beat(16)12
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-4.57%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.5%
Revenue beat(12)6
Avg Revenue beat(12)19.16%
Revenue beat(16)10
Avg Revenue beat(16)28.08%
PT rev (1m)10.68%
PT rev (3m)14.02%
EPS NQ rev (1m)-0.76%
EPS NQ rev (3m)-10.79%
EPS NY rev (1m)1.06%
EPS NY rev (3m)-3.66%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)-9.44%
Revenue NY rev (1m)-1.46%
Revenue NY rev (3m)-3.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.36 | ||
| Fwd PE | 10.6 | ||
| P/S | 1.3 | ||
| P/FCF | 20.27 | ||
| P/OCF | 13.14 | ||
| P/B | 1.54 | ||
| P/tB | 10.43 | ||
| EV/EBITDA | 5.31 |
EPS(TTM)3.86
EY6.96%
EPS(NY)5.23
Fwd EY9.44%
FCF(TTM)2.73
FCFY4.93%
OCF(TTM)4.22
OCFY7.61%
SpS42.77
BVpS36.09
TBVpS5.31
PEG (NY)1.72
PEG (5Y)2.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9% | ||
| ROE | 15.37% | ||
| ROCE | 19.55% | ||
| ROIC | 15.58% | ||
| ROICexc | 16.79% | ||
| ROICexgc | 53.71% | ||
| OM | 22.04% | ||
| PM (TTM) | 12.97% | ||
| GM | 70.04% | ||
| FCFM | 6.39% |
ROA(3y)5.07%
ROA(5y)6.23%
ROE(3y)8.63%
ROE(5y)10.88%
ROIC(3y)7.46%
ROIC(5y)7.05%
ROICexc(3y)8.27%
ROICexc(5y)7.94%
ROICexgc(3y)35.84%
ROICexgc(5y)35.27%
ROCE(3y)9.37%
ROCE(5y)8.86%
ROICexcg growth 3Y-11.4%
ROICexcg growth 5Y0.08%
ROICexc growth 3Y1.08%
ROICexc growth 5Y3.67%
OM growth 3Y0.02%
OM growth 5Y3.47%
PM growth 3Y-6.53%
PM growth 5Y12.13%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 3.04 | ||
| Debt/EBITDA | 0.56 | ||
| Cap/Depr | 89.1% | ||
| Cap/Sales | 3.47% | ||
| Interest Coverage | -34.57 | ||
| Cash Conversion | 38.03% | ||
| Profit Quality | 49.3% | ||
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | N/A |
F-Score7
WACC7.35%
ROIC/WACC2.12
Cap/Depr(3y)72.19%
Cap/Depr(5y)66.85%
Cap/Sales(3y)6.19%
Cap/Sales(5y)5.87%
Profit Quality(3y)111.96%
Profit Quality(5y)103.11%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.99%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-53.61%
EPS Next Y8.37%
EPS Next 2Y9.02%
EPS Next 3Y8.18%
EPS Next 5Y8.23%
Revenue 1Y (TTM)30.3%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-12.62%
Revenue Next Year3.46%
Revenue Next 2Y5.06%
Revenue Next 3Y5.29%
Revenue Next 5Y4.33%
EBIT growth 1Y21.75%
EBIT growth 3Y4.19%
EBIT growth 5Y6.9%
EBIT Next Year37.04%
EBIT Next 3Y15.5%
EBIT Next 5Y10.86%
FCF growth 1Y-18.63%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y-11.47%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%